BACKGROUND: Taraxacum platycarpum has been investigated for its antiallergic activity in bronchial asthma, but few studies have been conducted to evaluate its efficacy for the treatment of atopic dermatitis (AD). OBJECTIVE: This study was designed to evaluate the efficacy of the extracts of Taraxacum platycarpum (AF-343) for the treatment of AD. Method: Seventy-five patients with AD were randomly assigned either to a low-dose, high-dose or control groups. AF-343 and placebo were ingested for 8 weeks. The SCORing Atopic Dermatitis (SCORAD) scores, skin hydration, transepidermal water loss (TEWL), eosinophil, total IgE, eosinophil catinonic protein and cytokines were measured before and at the end of treatment. RESULT: A significant reduction in the SCORAD scores at the end of treatment were observed in the control, low-dose and high-dose groups when compared with the initial scores (P=0.028, P<0.001 and P<0.001, respectively). High-dose treatment increased the skin hydration (P=0.013), but no significant change was observed in the low-dose and control groups (P=0.056 and P=0.624, respectively). The low-dose and high-dose treatment groups showed a significant reduction of TEWL from baseline (P=0.002 and P=0.031, respectively). High-dose treatment induced an increase in eotaxin and a decrease in IL-5 (P=0.021 and P=0.028, respectively). CONCLUSION: These results show that AF-343 treatment can improve the severity and skin hydration in patients with mild AD.